# Neurogene Inc. (NGNE)

Source: https://www.quantisnow.com/company/NGNE
Generated: 2026-11-02T07:18:19.963Z

- Ticker: NGNE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- SEC CIK: 0001404644

## Latest NGNE news and filings

- 2026-10-27 11:30 UTC [Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome](https://www.quantisnow.com/insight/neurogene-presents-new-data-at-esgct-congress-that-reinforce-key-6758489)
- 2026-10-20 11:30 UTC [Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress](https://www.quantisnow.com/insight/neurogene-announces-upcoming-presentations-highlighting-key-differentiators-of-ngn-401-for-6751413)
- 2026-10-08 12:51 UTC [Analyst Coverage Initiated] [Analyst initiated coverage on Neurogene with a new price target](https://www.quantisnow.com/insight/analyst-initiated-coverage-on-neurogene-with-a-new-price-target-6741301)
- 2026-10-07 15:07 UTC [SEC Form SCHEDULE 13G filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-neurogene-inc-6740069)
- 2026-10-06 17:49 UTC [SEC Form SCHEDULE 13G filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-neurogene-inc-6738692)
- 2026-10-05 20:01 UTC [Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6736639)
- 2026-10-02 18:49 UTC [SEC Form 4] [Chief Executive Officer Mcminn Rachel exercised 756 shares at a strike of $25.32, increasing direct ownership by 0.06% to 1,345,063 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-mcminn-rachel-exercised-756-shares-at-a-6734099)
- 2026-09-08 11:30 UTC [Conference Announcement] [Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/neurogene-to-participate-in-hc-wainwright-28th-annual-global-investment-6707437)
- 2026-09-04 20:01 UTC [Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6706634)
- 2026-08-14 10:05 UTC [SEC Form SCHEDULE 13G filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-neurogene-inc-6681687)
- 2026-08-11 20:57 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neurogene-inc-6676348)
- 2026-08-11 11:32 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-results-of-operations-and-6674943)
- 2026-08-11 11:30 UTC [Public Offering] [Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates](https://www.quantisnow.com/insight/neurogene-reports-second-quarter-2026-financial-results-and-highlights-recent-6674929)
- 2026-08-04 20:01 UTC [Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6661854)
- 2026-07-28 11:00 UTC [Leadership Update] [Newleos Names Rohan Palekar as Board Chairman](https://www.quantisnow.com/insight/newleos-names-rohan-palekar-as-board-chairman-6650534)
- 2026-07-08 01:08 UTC [SEC Form 4] [President and CFO Cvijic Christine Mikail sold $173,375 worth of shares (4,800 units at $36.12) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-and-cfo-cvijic-christine-mikail-sold-173375-worth-of-6630670)
- 2026-07-06 20:01 UTC [Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6627952)
- 2026-07-02 22:42 UTC [SEC Form 4] [President and CFO Cvijic Christine Mikail sold $166,586 worth of shares (4,800 units at $34.71) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-and-cfo-cvijic-christine-mikail-sold-166586-worth-of-6626760)
- 2026-07-02 00:02 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-entry-into-a-material-6624002)
- 2026-07-01 23:58 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-neurogene-inc-6623998)
- 2026-07-01 11:00 UTC [Public Offering] [Neurogene Inc. Announces Pricing of $125 Million Public Offering](https://www.quantisnow.com/insight/neurogene-inc-announces-pricing-of-125-million-public-offering-6621729)
- 2026-06-30 20:19 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-neurogene-inc-6620931)
- 2026-06-30 20:01 UTC [Public Offering] [Neurogene Inc. Announces Proposed Public Offering](https://www.quantisnow.com/insight/neurogene-inc-announces-proposed-public-offering-6620676)
- 2026-06-29 12:00 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6618337)
- 2026-06-29 11:00 UTC [Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome](https://www.quantisnow.com/insight/neurogene-reports-positive-long-term-clinical-data-from-phase-12-trial-6618182)
- 2026-06-16 21:32 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Woods Keith](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-woods-keith-6605373)
- 2026-06-16 21:32 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Woods Keith](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-woods-keith-6605371)
- 2026-06-16 21:31 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director Woods Keith](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-woods-keith-6605370)
- 2026-06-16 21:30 UTC [SEC Form 3] [Amendment: SEC Form 3 filed by new insider Woods Keith](https://www.quantisnow.com/insight/amendment-sec-form-3-filed-by-new-insider-woods-keith-6605362)
- 2026-06-08 11:32 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6592553)
- 2026-06-08 11:30 UTC [Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome](https://www.quantisnow.com/insight/neurogene-announces-successful-completion-of-dosing-in-embolden-registrational-trial-6592536)
- 2026-06-04 20:41 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-submission-of-matters-to-6589745)
- 2026-06-03 12:11 UTC [Analyst Coverage Initiated] [Rodman & Renshaw initiated coverage on Neurogene with a new price target](https://www.quantisnow.com/insight/rodman-renshaw-initiated-coverage-on-neurogene-with-a-new-price-6585954)
- 2026-06-02 20:01 UTC [Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/neurogene-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6583984)
- 2026-05-12 20:06 UTC [SEC Form 8-K] [Neurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurogene-inc-filed-sec-form-8-k-results-of-operations-and-6547988)
- 2026-05-12 20:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neurogene Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neurogene-inc-6547913)
- 2026-05-12 20:05 UTC [Conference Announcement] [Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates](https://www.quantisnow.com/insight/neurogene-reports-first-quarter-2026-financial-results-and-highlights-recent-6547833)
- 2026-05-12 10:00 UTC [Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy](https://www.quantisnow.com/insight/neurogene-highlights-data-at-asgct-meeting-supporting-therapeutic-rationale-for-6546341)
- 2026-05-08 15:51 UTC [SEC Form 4] [President and CFO Cvijic Christine Mikail sold $300,043 worth of shares (9,600 units at $31.25) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-and-cfo-cvijic-christine-mikail-sold-300043-worth-of-6541507)
- 2026-05-07 16:35 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Shafer Christina](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-shafer-christina-6538287)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NGNE
- Earnings history: https://www.quantisnow.com/earnings/NGNE
- Dividend history: https://www.quantisnow.com/dividends/NGNE
- Insider transactions: https://www.quantisnow.com/insiders/NGNE
- Options chain: https://www.quantisnow.com/options/NGNE
- SEC 8-K filings only: https://www.quantisnow.com/company/NGNE/8-k
- RSS and alerts for NGNE: https://www.quantisnow.com/docs/rss-feeds.md